GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (STU:4K4) » Definitions » Book Value per Share

Stayble Therapeutics AB (STU:4K4) Book Value per Share : €0.06 (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Stayble Therapeutics AB Book Value per Share?

Stayble Therapeutics AB's book value per share for the quarter that ended in Sep. 2023 was €0.06.

During the past 12 months, Stayble Therapeutics AB's average Book Value Per Share Growth Rate was -48.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Stayble Therapeutics AB was 51.90% per year. The lowest was 23.50% per year. And the median was 37.70% per year.

Stayble Therapeutics AB's current price is €0.0158. Its book value per share for the quarter that ended in Sep. 2023 was €0.06. Hence, today's PB Ratio of Stayble Therapeutics AB is 0.26.

During the past 7 years, the highest P/B Ratio of Stayble Therapeutics AB was 6.91. The lowest was 0.00. And the median was 0.00.


Stayble Therapeutics AB Book Value per Share Historical Data

The historical data trend for Stayble Therapeutics AB's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stayble Therapeutics AB Book Value per Share Chart

Stayble Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Book Value per Share
Get a 7-Day Free Trial 0.08 - 0.17 0.27 0.10

Stayble Therapeutics AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.10 0.07 0.08 0.06

Competitive Comparison of Stayble Therapeutics AB's Book Value per Share

For the Biotechnology subindustry, Stayble Therapeutics AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stayble Therapeutics AB's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's PB Ratio distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's PB Ratio falls into.



Stayble Therapeutics AB Book Value per Share Calculation

Stayble Therapeutics AB's Book Value Per Share for the fiscal year that ended in Dec. 2022 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1.39-0.00)/14.23
=0.10

Stayble Therapeutics AB's Book Value Per Share for the quarter that ended in Sep. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(1.93-0.00)/31.72
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Stayble Therapeutics AB  (STU:4K4) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Stayble Therapeutics AB Book Value per Share Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Stayble Therapeutics AB (STU:4K4) Business Description

Traded in Other Exchanges
Address
Medicinaregatan 8a, Gothenburg, SWE, SE-413 90
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (STU:4K4) Headlines

No Headlines